FDA approves Roche's avetin ® combined chemotherapy (caplatinum and yewalcohol) for treatment of patients with advanced ovarian cancer
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, the Swiss Roche Group announced that the U.SFDA(approved an avetin ® (bevazumab) combined chemotherapy (caplatinum and yew alcohol) for the treatment of patients with advanced (III or IV) ovarian cancer after initial surgery, followed by the use of anvitamintinmono therapythis approval is based on the phase III Key ClinicalTrialdata show edgy: patients continue to use avestine monotherapy after receiving acombination chemotherapy, the median progression survival (PFS) reached 18.2 months; 95% CI 0.52 - 0.75, p 0.0001This PFS benefit is based on a fixed treatment cycle (a total of 22 courses of treatment for Amvetin), anavetin has been approved for 10 indications in the United States, involving 6 cancersThe approval is the fourth gynaecological oncology approved by Amvetin in four years, and three other indications include advanced cervical cancer, as well as two types of ovarian cancer that has been given platinumdrug(based on chemotherapy that recurs after chemotherapy)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
